USPTO Examiner WESTERBERG NISSA M - Art Unit 1618

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18812148RAPID FORMING ARTIFICIAL BLOOD VESSEL AND PREPARATION METHODAugust 2024November 2025Abandon1520NoNo
18787389CANCER TREATMENTS USING COMBINATIONS OF CDK AND ERK INHIBITORSJuly 2024November 2025Allow1610YesNo
18621526SUPRAMOLECULAR IONIZABLE LIPID MOLECULES WITH HETEROATOMIC TUNING FOR NUCLEIC ACID DELIVERYMarch 2024June 2025Allow1421YesNo
18600459CHEMICAL COMPOSITION FOR ENTERIC DRUG DELIVERYMarch 2024November 2025Abandon2021NoNo
18402112BAMBOO CHARCOAL POWDER-BASED FALSE EYELASHES AND PREPARATION PROCESS THEREOFJanuary 2024March 2025Allow1441NoNo
18558015Compositions and Methods for Targeting Lipid Nanoparticle Therapeutics to Stem CellsOctober 2023February 2026Abandon2721NoNo
18244155TOPICAL AMLODIPINE SALTS FOR THE TREATMENT OF ANORECTAL DISEASESSeptember 2023January 2025Abandon1610NoNo
18462701FIBRIN PARTICLES AND METHODS OF MAKING THE SAMESeptember 2023May 2025Allow2011NoNo
18351952COLORING ULTRAVIOLET PROTECTIVE AGENTJuly 2023June 2025Abandon2321NoNo
18445165Formulated and/or Co-Formulated Liposome Compositions Containing Toll-like Receptor("TLR") Agonist Prodrugs Useful In The Treatment of Cancer and Methods ThereofMay 2023November 2024Allow1810YesNo
18310034CANCER TREATMENTS USING COMBINATIONS OF CDK AND ERK INHIBITORSMay 2023April 2024Allow1211YesNo
18308597Octreotide Depot Formulation with Constantly High Exposure LevelsApril 2023October 2024Abandon1810NoNo
18445035Formulated and/or co-formulated liposome compositions containing toll-like receptor ("TLR") agonist prodrugs useful in the treatment of cancer and methods thereofMarch 2023March 2025Abandon2430NoNo
18022192[18F]-LABELED IMIDAZOPYRIDINE DERIVATIVES AS PET RADIOTRACERFebruary 2023November 2025Allow3210YesNo
18087087PEPTIDE-NANOPARTICLE CONJUGATESDecember 2022September 2025Abandon3331NoNo
18086058NOVEL FORMULATION OF MELOXICAMDecember 2022May 2024Abandon1610NoNo
18057607DENDRIMER COMPOSITIONS AND THEIR USE IN TREATMENT OF DISEASES OF THE EYENovember 2022December 2024Abandon2421NoNo
18054065NANOSYSTEMS AS SELECTIVE VEHICLESNovember 2022January 2026Allow3831YesNo
17803703Formulated and/or Co-Formulated Liposome Compositions Containing Toll--Like Receptor ("TLR") Agonist Prodrugs Useful In The Treatment of Cancer and Methods ThereofOctober 2022September 2023Allow1001YesNo
17905623COLLOIDAL CARRIER SYSTEMS FOR TRANSFER OF AGENTS TO A DESIRED SITE OF ACTIONSeptember 2022October 2025Abandon3801NoNo
17797819NERVE SPECIFIC FLUOROPHORE FORMULATIONS FOR DIRECT AND SYSTEMIC ADMINISTRATIONAugust 2022February 2025Abandon3121NoNo
17817030Mechano-Sensitive Microcapsules For Drug DeliveryAugust 2022November 2024Allow2831YesNo
17794932OXAZINE-BASED FLUOROPHORE COMPOUNDS FOR NERVE-SPECIFIC IMAGINGJuly 2022December 2025Allow4111YesNo
17864077ULTRA-DEFORMABLE LIPOSOMES FOR DRUG DELIVERYJuly 2022February 2026Abandon4331NoNo
17791824SUSTAINED IMMUNOTHERAPYJuly 2022November 2025Abandon4101NoNo
17859537POLYETHYLENIMINE NANOPARTICLES AND METHODS OF USING SAMEJuly 2022April 2024Abandon2111NoNo
17845208PHOSPHOCALCIC CEMENT COMPOSITION COMPRISING BLOODJune 2022March 2025Abandon3341YesNo
17753893METHODS FOR TRIGGERING M1 MACROPHAGE POLARIZATIONMarch 2022October 2025Abandon4301NoNo
17668272ANTI-TUMORAL COMPOUND AND RELATIVE PRODUCTION PROCESSFebruary 2022November 2023Abandon2110NoNo
17583498FUNGAL IRON ACQUISITION INHIBITORS AND USES THEREOFJanuary 2022May 2023Allow1610YesNo
17581366Novel nanobubble that contains epilepsy medicine. The bubble polarizes in presence of the electric surge generated in the brain during an epilepsy attack and automatically discharges the medicine at the time and the site of the attack, stopping the seizure in its infancy without any external intervention. The bubble releases just enough medication into the bloodstream, significantly reducing side effects.January 2022March 2024Abandon2610YesNo
17597515COMPOUNDS USEFUL FOR INHIBITING BFL1 AND THEIR USE IN THERAPYJanuary 2022July 2025Allow4251YesNo
17560820IMMUNOSTIMULATORY LIPOPLEX, PHARMACEUTICAL COMPOSITION INCLUDING IMMUNOSTIMULATORY LIPOPLEX, AND USES THEREOFDecember 2021April 2025Abandon4031NoNo
17644215MOISTURIZING COMPOSITIONS AND USES THEREOFDecember 2021October 2023Abandon2210NoNo
17534146MICROPARTICLES AND NANOPARTICLES HAVING SULFATE GROUPS ON THE SURFACENovember 2021May 2024Allow2911YesNo
17524211METHODS OF TREATING CANCER BY TARGETING TUMOR-ASSOCIATED MACROPHAGESNovember 2021January 2025Abandon3941NoNo
17520972WATER-SOLUBLE COMPOUND FOR DETECTION OF BETA-AMYLOIDNovember 2021October 2025Allow4821NoNo
17517621Microbubble-extracellular vesicle complexesNovember 2021September 2024Allow3531YesNo
17516289Synthetic Scaffolds for Metastasis DetectionNovember 2021September 2024Abandon3421NoYes
17512124TUNABLE IMMUNE RESPONSIVE BIODEGRADABLE ARGININE-BASED POLY(ESTER AMIDE)S AND METHODS OF MAKING AND USING SAMEOctober 2021April 2024Abandon3021NoNo
17511864BIOPSY DEVICE MARKER AND RELATED METHODSOctober 2021January 2026Abandon5121YesNo
17503553MULTI-PHASE ORAL COMPOSITION FOR TOOTH WHITENINGOctober 2021September 2024Allow3520NoNo
17598558METHOD OF PREPARING NANOPLATEFORM-BASED DIAGNOSTIC AGENT FOR SELECTIVELY STAINING OF INFLAMMATORY ABNORMAL TISSUE OR TUMOR TISSUESeptember 2021June 2025Abandon4501NoNo
17479400COMPOSITIONS AND METHODS FOR TREATMENT OF PEROXISOMAL DISORDERS AND LEUKODYSTROPHIESSeptember 2021March 2024Abandon3021NoNo
17472502IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF BUPRENORPHINESeptember 2021July 2023Abandon2210NoNo
17460743CANCER TREATMENTS USING COMBINATIONS OF CDK AND ERK INHIBITORSAugust 2021February 2023Allow1701YesNo
17305916TOPICAL AMLODIPINE SALTS FOR THE TREATMENT OF ANORECTAL DISEASESJuly 2021May 2023Allow2211YesNo
17423108MICROCAPSULE COMPOSITION USING ALGINATE GEL, AND METHOD FOR PRODUCING SAMEJuly 2021January 2026Abandon5461NoNo
17376099METHOD OF ADMINISTERING LOCAL ANESTHETIC SOLUTION FOR DENTAL AND/OR CONTRAST MEDIA USEJuly 2021October 2025Abandon5151YesYes
17421607Manganese Ferrite Nanoparticles for Use as MRI Contrast Agents and Magnetohypothermia AgentsJuly 2021May 2025Abandon4631NoNo
17421005DRUG DELIVERY PLATFORM USING W/O/W-TYPE TRIOLEIN EMULSION PROMOTIVE OF BLOOD-BRAIN BARRIER OPENINGJuly 2021December 2024Abandon4141YesNo
17419937POLYMERSOMES FUNCTIONALISED WITH MULTIPLE LIGANDSJune 2021February 2025Allow4331YesNo
17416592SLEEP MODULATION AGENTJune 2021May 2025Abandon4711NoNo
17416284CONJUGATESJune 2021October 2025Abandon5111NoNo
17348258FUNCTIONALIZED SUPERABSORBENT MATERIAL FOR USE IN LESION PHANTOMJune 2021July 2025Allow4921YesNo
17303878ENCAPSULATION AND HIGH ENCAPSULATION EFFICIENCY OF PHOSPHORYLATED ACTIVE AGENTS IN NANOPARTICLESJune 2021September 2025Abandon5261YesNo
17343095MEDICAL ITEM FOR PREVENTION AND TREATMENT OF EAR INFECTIONJune 2021August 2023Abandon2610NoNo
17311679FIBRIN-TARGETED POLYMERIZED SHELL LIPID MICROBUBBLES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONSJune 2021December 2023Abandon3001NoNo
17298436DENDRIMER FOR THERAPY AND IMAGINGMay 2021June 2025Abandon4921NoNo
17295457PHOTOCHEMICALLY INDUCED CONJUGATION OF RADIOMETALS TO SMALL MOLECULES, PEPTIDES AND NANOPARTICLES IN A SIMULTANEOUS ONE-POT REACTIONMay 2021December 2024Abandon4201NoNo
17290906ALGINIC ACID-BASED INJECTABLE HYDROGEL SYSTEMMay 2021April 2025Abandon4821NoNo
17290337Methods for Synthesis of Radionuclide ComplexApril 2021June 2025Abandon4921NoNo
17240117FUSOGENIC LIPOSOMES FOR SELECTIVE IMAGING OF TUMOR CELLSApril 2021August 2023Abandon2801NoNo
17287748DENDRITIC POLYMERS COMPLEXED WITH IMMUNE CHECKPOINT INHIBITORS FOR ENHANCED CANCER IMMUNOTHERAPYApril 2021December 2025Abandon5631YesNo
17300227Formulated and/or co-furmulated liposome compositions containing toll-like receptor ("TLR") agonist prodrugs useful in the treatment of cancer and methods thereofApril 2021December 2022Allow2001YesNo
17265988MONOAMINE OXIDASE B IMAGING PROBEApril 2021November 2025Allow5741YesNo
17285281Nanostructured Lipid Gel, Method for Preparation and UseApril 2021November 2024Allow4310YesNo
17285194RADIOLIGANDS FOR IMAGING THE LPA1 RECEPTORApril 2021November 2024Abandon4311NoNo
17208405Makeup Cosmetic Having Improved Impregnated MaterialMarch 2021May 2024Abandon3720YesNo
17271562COMBINATION OF PI3K-INHIBITORS AND TARGETED THORIUM CONJUGATESFebruary 2021June 2024Abandon4001NoNo
17270946RADIOACTIVE IMIDAZOTHIADIAZOLE DERIVATIVE COMPOUNDFebruary 2021June 2024Abandon3901NoNo
17177370Compositions And Methods For Attracting InsectsFebruary 2021May 2023Abandon2701NoNo
17171836Octreotide Depot Formulation with Constantly High Exposure LevelsFebruary 2021June 2023Abandon2810NoNo
17153123METHOD OF PREPARING A COSMETIC COMPOSITIONJanuary 2021April 2025Abandon5120NoYes
17142698Polymeric Prodrugs with a Self-Immolative LinkerJanuary 2021October 2025Abandon5731YesYes
17131956COLOR CHANGING SILK PATCH FOR VISIBLE ROS DETECTIONDecember 2020August 2025Abandon5671YesNo
17255242TUNABLE IMMUNE RESPONSIVE BIODEGRADABLE ARGININE-BASED POLY(ESTER AMIDE)S AND METHODS OF MAKING AND USING SAMEDecember 2020March 2022Abandon1511NoNo
16974306Formulated and/or co-formulated liposome compositions containing toll-like receptor ("TLR") agonist prodrugs useful in the treatment of cancer and methods thereofDecember 2020December 2022Allow2401YesNo
17123941ENCAPSULATED CELLS PRODUCING CYTOCHROME P450 AND METHODS OF USE THEREOFDecember 2020June 2023Abandon3021NoNo
17116357MITOCHONDRIAL COPPER DEPLETION REPROGRAMS THE METABOLISM OF TRIPLE NEGATIVE BREAST CANCERDecember 2020May 2023Abandon2901NoNo
16972798TMEM-MCD IN THE MINIMALLY INVASIVE ASSESSMENT OF THE ACTIVITY STATUS OF TMEM IN ITS DISSEMINATION OF TUMOR CELLSDecember 2020July 2024Abandon4351YesNo
17106141METHODS AND DEVICES FOR LYMPHATIC TARGETINGNovember 2020November 2024Abandon4750NoYes
16951736METHOD OF TRANSPORTING AN AGENT ACROSS BLOOD-BRAIN, BLOOD-COCHLEAR OR BLOOD-CEREBROSPINAL FLUID BARRIERNovember 2020September 2022Abandon2201YesNo
17099568NEUROACTIVE STEROIDS AND COMPOSITIONS AND METHODS THEREOFNovember 2020May 2023Abandon3001NoNo
17090347METHOD FOR IMPROVING SKIN WHITENING POWER OF A SKIN WHITENING AGENTNovember 2020September 2023Abandon3420YesNo
17051507DRUG DELIVERYOctober 2020October 2024Abandon4821NoNo
17083601PEPTIDE-NANOPARTICLE CONJUGATESOctober 2020September 2022Allow2311YesNo
17076600PRECISION CHEMICAL ABLATION AND TREATMENT OF TISSUESOctober 2020January 2026Abandon6061YesYes
17075882Epilatory CompositionsOctober 2020December 2021Allow1400YesNo
17075758Epilatory CompositionsOctober 2020December 2021Allow1400YesNo
17064348STABLE EMULSIFIED GEL COMPOSITION HAVING A HIGH CONCENTRATION OF ACTIVE COMPONENTSOctober 2020June 2023Abandon3231YesNo
17044189STEREOCOMPLEX OF OLIGOLACTIC ACID CONJUGATES IN MICELLES FOR IMPROVED PHYSICAL STABILITY AND ENHANCED ANTITUMOR EFFICACYSeptember 2020September 2022Abandon2331YesNo
16981432PSMA-TARGETED RADIOPHARMACEUTICAL FOR DIAGNOSING AND TREATING PROSTATE CANCERSeptember 2020December 2023Allow3901YesNo
17017473NOVEL FORMULATION OF MELOXICAMSeptember 2020February 2023Abandon2910NoNo
16979059METHOD FOR OBTAINING PROTEINS OR A RICH-PROTEIN EXTRACT FROM ALGAE, EXTRACTS AND USES THEREFORESeptember 2020November 2024Abandon5021NoNo
16978479Dyes for Analysis of Soluble Protein Aggregates or Misfolded Protein OligomersSeptember 2020June 2024Abandon4501NoNo
16970975POROUS EMBOLIZATION MICROSPHERES COMPRISING DRUGSAugust 2020November 2024Abandon5121NoNo
16989041Complex, Preparation Methods and Application ThereofAugust 2020January 2024Abandon4141NoNo
16962196NANOSYSTEMS AS SELECTIVE VEHICLESJuly 2020January 2023Abandon3021NoNo
16958962LIPOCALIN-TYPE PROSTAGLANDIN D2 SYNTHASE PRODUCTION PROMOTING AGENTJune 2020November 2023Abandon4121YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WESTERBERG, NISSA M.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
65
Examiner Affirmed
48
(73.8%)
Examiner Reversed
17
(26.2%)
Reversal Percentile
42.3%
Lower than average

What This Means

With a 26.2% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
217
Allowed After Appeal Filing
42
(19.4%)
Not Allowed After Appeal Filing
175
(80.6%)
Filing Benefit Percentile
23.9%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 19.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner WESTERBERG, NISSA M - Prosecution Strategy Guide

Executive Summary

Examiner WESTERBERG, NISSA M works in Art Unit 1618 and has examined 982 patent applications in our dataset. With an allowance rate of 23.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 44 months.

Allowance Patterns

Examiner WESTERBERG, NISSA M's allowance rate of 23.7% places them in the 3% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by WESTERBERG, NISSA M receive 2.94 office actions before reaching final disposition. This places the examiner in the 85% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by WESTERBERG, NISSA M is 44 months. This places the examiner in the 14% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +41.6% benefit to allowance rate for applications examined by WESTERBERG, NISSA M. This interview benefit is in the 88% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 6.0% of applications are subsequently allowed. This success rate is in the 3% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 12.2% of cases where such amendments are filed. This entry rate is in the 12% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 57.8% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 49% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 52.6% of appeals filed. This is in the 23% percentile among all examiners. Of these withdrawals, 44.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 74.4% are granted (fully or in part). This grant rate is in the 80% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 1.3% of allowed cases (in the 70% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.